Abstract: A method is provided to place new slides on zooming user interface canvas is provided that includes: receiving user request to add a new slide; determining whether a zoom level of a current viewing window has changed to meet a prescribed threshold zoom level since addition of a previously added slide; in response to a determination that the zoom level has changed, using a current viewing window zoom level as a reference zoom level; in response to a determination that the zoom level has not changed, using a previous viewing window zoom level as the reference zoom level; and determining a placement of the new slide with reference to the reference zoom level.

Abstract: A method is provided to place new slides on zooming user interface canvas is provided that includes: receiving user request to add a new slide; determining whether a zoom level of a current viewing window has changed to meet a prescribed threshold zoom level since addition of a previously added slide; in response to a determination that the zoom level has changed, using a current viewing window zoom level as a reference zoom level; in response to a determination that the zoom level has not changed, using a previous viewing window zoom level as the reference zoom level; and determining a placement of the new slide with reference to the reference zoom level.

Abstract: A method is provided to place new slides on zooming user interface canvas is provided that includes: receiving user request to add a new slide; determining whether a zoom level of a current viewing window has changed to meet a prescribed threshold zoom level since addition of a previously added slide; in response to a determination that the zoom level has changed, using a current viewing window zoom level as a reference zoom level; in response to a determination that the zoom level has not changed, using a previous viewing window zoom level as the reference zoom level; and determining a placement of the new slide with reference to the reference zoom level.

Abstract: A method is provided method to control a computer generated presentation using a two-dimensional (2D) zooming user interface, the method comprising: providing on the display screen multiple respective thumbnail images that correspond to the multiple screen images displayed within the presentation; and in response to receipt of user input selecting one thumbnail image followed by receipt of user input selecting another of the thumbnail image, displaying on the display screen a screen image that corresponds to the user selected one thumbnail image followed by display on the display screen of another thumbnail image that corresponds to the user selected another thumbnail image and display of at least one of panning and zooming between display of the one thumbnail image and the another thumbnail image.

Abstract: An apparatus and method for 3D rendering of a canvas and at least a first background in a ZUI environment are disclosed herein. Within a viewing window, display at least a portion of the canvas and at least a portion of the first background in parallax. Receive a user action taken on the viewing window that triggers a change in the displaying of the canvas and the first background. Calculate a first transform value and a first transparency value for the first background, in response to the received user action. Update the display of the canvas and the first background in response to the received user action, the canvas updated in accordance with the received user action and the first background updated in accordance with the first transform value and the first transparency value.

Abstract: A method is provided to place new slides on zooming user interface canvas is provided that includes: receiving user request to add a new slide; determining whether a zoom level of a current viewing window has changed to meet a prescribed threshold zoom level since addition of a previously added slide; in response to a determination that the zoom level has changed, using a current viewing window zoom level as a reference zoom level; in response to a determination that the zoom level has not changed, using a previous viewing window zoom level as the reference zoom level; and determining a placement of the new slide with reference to the reference zoom level.

Abstract: An apparatus and method for 3D rendering of a canvas and at least a first background in a ZUI environment are disclosed herein. Within a viewing window, display at least a portion of the canvas and at least a portion of the first background in parallax. Receive a user action taken on the viewing window that triggers a change in the displaying of the canvas and the first background. Calculate a first transform value and a first transparency value for the first background, in response to the received user action. Update the display of the canvas and the first background in response to the received user action, the canvas updated in accordance with the received user action and the first background updated in accordance with the first transform value and the first transparency value.

Abstract: A method is provided method to control a computer generated presentation using a two-dimensional (2D) zooming user interface, the method comprising: providing on the display screen multiple respective thumbnail images that correspond to the multiple screen images displayed within the presentation; and in response to receipt of user input selecting one thumbnail image followed by receipt of user input selecting another of the thumbnail image, displaying on the display screen a screen image that corresponds to the user selected one thumbnail image followed by display on the display screen of another thumbnail image that corresponds to the user selected another thumbnail image and display of at least one of panning and zooming between display of the one thumbnail image and the another thumbnail image.

Abstract: The invention relates to the inclusion complexes of 7-isopropoxy-isoflavon formed with cyclodextrin or cyclodextrin derivatives as well as to the pharmaceutical compositions containing these inclusion complexes as active ingredient. The invention further relates to the preparation of the new inclusion complexes.The new inclusion complex according to the invention shows higher dissolution and resorption properties as compared to the active ingredient administered per se.

Abstract: The invention relates to novel diphenylpropylamine derivatives of the general formula (I). ##STR1## R.sup.1 stands for hydrogen or a methyl group; R.sup.2 stands for hydrogen, a methyl or n-decyl group;Z means a phenyl group substituted by R.sup.3, R.sup.4 and R.sup.5, whereinR.sup.3 means hydrogen, fluorine, chlorine or bromine, or a nitro, C.sub.1-12 alkyl, C.sub.1-4 alkoxy, phenoxy or benzyloxy group;R.sup.4 and R.sup.5 represent hydrogen, chlorine or a hydroxy, alkoxy, benzyloxy, acetamino or carboxy group; orR.sup.4 and R.sup.5 together form a methylendioxy group;orZ may stand for a 4-methoxynaphtyl or 4-ethoxy-naphthyl group; andR.sup.6 stands for hydrogen or fluorine, with the proviso that each of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 cannot simultaneously stand for hydrogen, as well as their physiologically acceptable acid addition salts.The invention also relates to a process for the preparation of these compounds and to the pharmaceutical compositions containing these compounds.

Abstract: Diuretic and saluretic tetrahydro-isoquinoline derivatives of the Formula (I) ##STR1## wherein R stands for hydrogen or chlorine,R.sup.1 and R.sup.2 are hydrogen, methoxy or ethoxy, andR.sup.3 and R.sup.4 are hydrogen or methyl,and a process for the preparation thereof as well as pharmaceutical compositions containing as active ingredients isoquinoline derivatives of the Formula (I). The compounds of Formula I are prepared by reacting a 2-amino-tetrahydro-isoquinoline derivative of the Formula (II) ##STR2## with a carboxylic acid derivative of the Formula (III) ##STR3## wherein x stands for chlorine, --OH, --OCH.sub.2 CN, --OCH.sub.3, --OC.sub.2 H.sub.5, --OCOOCH.sub.3 or --OCOOC.sub.2 H.sub.5R.sup.5 and R.sup.6 stand for hydrogen or together from CHN(CH.sub.3).sub.2 and in case of the Formula (Ia) ##STR4## splitting off the protective group in alkaline medium.

Abstract: The present invention relates to novel compounds of the general formula ##STR1## wherein R is hydrogen atom or a trifluoromethyl, carboxy, C.sub.2-5 alkoxycarbonyl, cyano, benzoyl, sulfamoyl or C.sub.1-4 alkylsulfonyl group;R.sup.1 is hydrogen atom or a linear or branched chain C.sub.1-4 alkyl, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfonyl, benzylthio, benzylsulfonyl, phenyl, hydroxy or mercapto group; andR.sup.2 is hydrogen or chlorine atom,as well as their pharmaceutically acceptable salts.The compounds according to the invention possess diuretic and saluretic activity with an advantageous Na/K ratio.

Abstract: The invention relates to new oxidiazole-alkyl-purine-derivatives of the Formula I ##STR1## and pharmaceutically acceptable salts thereof wherein A stands for C.sub.1-4 alkylene andR.sup.1 represents C.sub.1-6 alkyl, hydroxyalkyl, halogenoalkyl, carboxyalkyl, C.sub.5-6 cycloalkyl or aminoalkyl of the Formula --(CH.sub.2).sub.n --NR.sup.2 R.sup.3 in which group n is an integer 1-3; R.sup.2 and R.sup.3 each stand for hydrogen or C.sub.1-4 alkyl or together with the adjacent nitrogen atom they are attached to form a 5- or 6-membered nitrogen containing heterocyclic ring which may optionally comprise a further nitrogen atom or an oxygen atom as heteroatom; orR.sup.1 stands for phenyl, hydroxyphenyl, carboxyphenyl, benzyl or dimethoxybenzylThe compounds of the Formula I can be prepared by methods known per se and can be used in therapy as antitussive agents.

Abstract: The invention relates to the inclusion complexes of 7-isopropoxy-isoflavone formed with cyclodextrin or cyclodextrin derivatives as well as to the pharmaceutical compositions containing these inclusion complexes as active ingredient. The invention further relates to the preparation of the new inclusion complexes. The new inclusion complex according to the invention shows higher dissolution and resorption properties as compared to the active ingredient administered per se.